Risk factors for hematoma in patients undergoing cardiac device procedures: A WRAP-IT trial analysis.

Anticoagulation Antiplatelet Antithrombotic management CIED Complication Hematoma Risk factor

Journal

Heart rhythm O2
ISSN: 2666-5018
Titre abrégé: Heart Rhythm O2
Pays: United States
ID NLM: 101768511

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 20 05 2022
accepted: 30 05 2022
entrez: 7 11 2022
pubmed: 8 11 2022
medline: 8 11 2022
Statut: epublish

Résumé

Implant site hematoma is a known complication of cardiac device procedures and can lead to major consequences. To evaluate risk factors for hematoma and further understand the relationship between anticoagulant (AC), antiplatelet (AP) use, and hematoma development. We included 6800 patients from the WRAP-IT trial. To assess baseline and procedural characteristics associated with hematoma within the first 30 days postprocedure, a stepwise Cox regression model was implemented with minimal Akaike information criterion. Cox regressions were also used to evaluate AC/AP use and hematoma risk. The overall rate of hematoma was 2.2%. The model identified 11 baseline and procedural characteristics associated with hematoma risk. AC use (hazard ratio [HR]: 2.44, The results of this analysis highlight risk factors associated with the development of hematoma in patients undergoing CIED procedures and can inform antithrombotic management.

Sections du résumé

Background UNASSIGNED
Implant site hematoma is a known complication of cardiac device procedures and can lead to major consequences.
Objectives UNASSIGNED
To evaluate risk factors for hematoma and further understand the relationship between anticoagulant (AC), antiplatelet (AP) use, and hematoma development.
Methods UNASSIGNED
We included 6800 patients from the WRAP-IT trial. To assess baseline and procedural characteristics associated with hematoma within the first 30 days postprocedure, a stepwise Cox regression model was implemented with minimal Akaike information criterion. Cox regressions were also used to evaluate AC/AP use and hematoma risk.
Results UNASSIGNED
The overall rate of hematoma was 2.2%. The model identified 11 baseline and procedural characteristics associated with hematoma risk. AC use (hazard ratio [HR]: 2.44,
Conclusion UNASSIGNED
The results of this analysis highlight risk factors associated with the development of hematoma in patients undergoing CIED procedures and can inform antithrombotic management.

Identifiants

pubmed: 36340491
doi: 10.1016/j.hroo.2022.05.012
pii: S2666-5018(22)00142-8
pmc: PMC9626743
doi:

Types de publication

Journal Article

Langues

eng

Pagination

466-473

Informations de copyright

© 2022 Heart Rhythm Society. Published by Elsevier Inc.

Références

Europace. 2021 May 21;23(5):748-756
pubmed: 33367623
Heart Rhythm. 2021 Dec;18(12):2080-2086
pubmed: 34280568
Chest. 2004 Oct;126(4):1177-86
pubmed: 15486380
J Am Coll Cardiol. 2010 May 25;55(21):2376-82
pubmed: 20488310
Circulation. 2007 Sep 18;116(12):1349-55
pubmed: 17724263
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2915-2931
pubmed: 30522654
Circ Arrhythm Electrophysiol. 2010 Aug;3(4):312-8
pubmed: 20558847
Europace. 2017 Jun 01;19(6):1002-1006
pubmed: 27353323
Heart Rhythm. 2014 May;11(5):799-805
pubmed: 24444444
Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3135-6
pubmed: 26400510
Circulation. 2009 Mar 3;119(8):1078-84
pubmed: 19221223
Heart Rhythm. 2018 Mar;15(3):318-325
pubmed: 29141184
J Am Coll Cardiol. 2019 Jul 9;74(1):83-99
pubmed: 31272556
Circulation. 2013 Aug 27;128(9):1031-8
pubmed: 23979629
Circ J. 2002 Aug;66(8):746-50
pubmed: 12197599
Eur Heart J. 2010 Jan;31(2):203-10
pubmed: 19875388
J Am Coll Cardiol. 2016 Mar 22;67(11):1300-8
pubmed: 26988951
Circ Arrhythm Electrophysiol. 2020 May;13(5):e008280
pubmed: 32281393
Indian Pacing Electrophysiol J. 2016 Sep - Oct;16(5):159-164
pubmed: 27979375
N Engl J Med. 2013 May 30;368(22):2084-93
pubmed: 23659733
Int J Cardiol. 2019 Aug 1;288:87-93
pubmed: 31056413
Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3015-21
pubmed: 22923228
Circ Arrhythm Electrophysiol. 2019 Oct;12(10):e007545
pubmed: 31610718
Chest. 2012 Feb;141(2 Suppl):e326S-e350S
pubmed: 22315266
Europace. 2015 Aug;17(8):1197-214
pubmed: 26105732
Am Heart J. 2016 Oct;180:12-21
pubmed: 27659878
Heart Rhythm. 2020 Jul;17(7):1115-1122
pubmed: 32087357
Eur Heart J. 2018 Nov 21;39(44):3973-3979
pubmed: 30462279
N Engl J Med. 2019 May 16;380(20):1895-1905
pubmed: 30883056
Pacing Clin Electrophysiol. 2010 Apr;33(4):414-9
pubmed: 19793359
Europace. 2015 Oct;17(10):1548-54
pubmed: 25855676

Auteurs

Khaldoun G Tarakji (KG)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Panagiotis Korantzopoulos (P)

First Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece.

Francois Philippon (F)

Cardiology Department, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Quebec, Canada.

Mauro Biffi (M)

Cardiology, Policlinico Sant' Orsola, Malpighi, Italy.

Suneet Mittal (S)

Electrophysiology, Valley Health System, Ridgewood, New Jersey.

Jeanne E Poole (JE)

Division of Cardiology, University of Washington School of Medicine, Seattle, Washington.

Charles Kennergren (C)

Cardiothoracic Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.

Daniel R Lexcen (DR)

Cardiac Rhythm Management, Medtronic, Inc, Mounds View, Minnesota.

Jeff D Lande (JD)

Cardiac Rhythm Management, Medtronic, Inc, Mounds View, Minnesota.

Gregory Hilleren (G)

Cardiac Rhythm Management, Medtronic, Inc, Mounds View, Minnesota.

Swathi Seshadri (S)

Cardiac Rhythm Management, Medtronic, Inc, Mounds View, Minnesota.

Bruce L Wilkoff (BL)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Classifications MeSH